Options
CPT: Pharmacometrics and Systems Pharmacology Volume 12
ISSN
21638306
Date Issued
2023
Abstract
(Model-based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2-positive advanced or metastatic breast cancer patients - https://doi.org/10.1002/psp4.12910) -
(Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway - https://doi.org/10.1002/psp4.13026) -
(Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors - https://doi.org/10.1002/psp4.12962) -
(Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab - https://doi.org/10.1002/psp4.13000) -
(Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma - https://doi.org/10.1002/psp4.12922)
(Mixed effects modeling of radiotherapy in combination with immune checkpoint blockade or inhibitors of the DNA damage response pathway - https://doi.org/10.1002/psp4.13026) -
(Sabatolimab (MBG453) model-informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors - https://doi.org/10.1002/psp4.12962) -
(Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab - https://doi.org/10.1002/psp4.13000) -
(Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma - https://doi.org/10.1002/psp4.12922)
File(s)